<DOC>
	<DOCNO>NCT02109562</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety RBP-7000 compare placebo treatment patient schizophrenia .</brief_summary>
	<brief_title>Randomized , Double-blind , Placebo Controlled , Multi-center Tolerability RBP-7000 Schizophrenia Patients</brief_title>
	<detailed_description>This double-blind , placebo-controlled , Phase III study 90 mg 120 mg dos RBP-7000 compare placebo 8-week treatment period .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Males female age 18 55 year , inclusive Diagnosis schizophrenia define Diagnostic Statistical Manual , Edition 4 , text revision ( DSMIVTR ) criterion Subjects deem `` valid '' State , Assessability , Face , Ecological , Rule ( SAFER ) interview Subjects otherwise healthy basis physical examination Subjects improvement total Positive Negative Syndrome Scale ( PANSS ) score 20 % great initial screen visit first day treatment . Subjects take daily oral risperidone dose â‰¥ 6 mg/day Subjects receive depot antipsychotic within 120 day screen Subjects treatment resistant schizophrenia , judge investigator , treat antipsychotic adequate duration adequate dosage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophrenic</keyword>
	<keyword>Schizophrenias</keyword>
	<keyword>Risperidone</keyword>
</DOC>